Progesterone vs. synthetic progestins and the risk of breast cancer: A systematic review and meta-analysis

Systematic Reviews

Volumn 5, Issue 1, 2016, Pages

  Asi, Noor ^a,c   Mohammed, Khaled ^a   Haydour, Qusay ^a,b   Gionfriddo, Michael R ^a   Vargas, Oscar L Morey ^a   Prokop, Larry J ^a   Faubion, Stephanie S ^a   Murad, Mohammad Hassan ^a  

^a MAYO CLINIC   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Breast cancer; Cardiovascular events; Meta analysis; Progesterone; Synthetic progestins; Systematic review

Indexed keywords

ESTROGEN; GESTAGEN; PROGESTERONE; PROGESTERONE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; GLUCOSE METABOLISM; HORMONAL THERAPY; HUMAN; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMPARATIVE STUDY; ESTROGEN THERAPY; FEMALE; OBSERVATIONAL STUDY; RISK FACTOR;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PROGESTERONE; PROGESTERONE CONGENERS; PROGESTINS; RISK FACTORS;

EID: 84979210661     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/s13643-016-0294-5     Document Type: Article

References (24)

1. National Institutes of Health. National Institutes of Health state-of-the-science conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142:1003-13.
2. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc. 2011;86:673-80. quiz 680.
3. Stanczyk FZ, Hapgood JP, Winer S, Mishell Jr DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34:171-208.
4. Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P, Gompel A. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. 2012;131:49-63.
5. Lambrinoudaki I. Progestogens in postmenopausal hormone therapy and the risk of breast cancer. Maturitas. 2014;77:311-7.
6. Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT. Prescribing menopausal hormone therapy: an evidence-based approach. Int J Women's Health. 2014;6:47-57.
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SAA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama. 2002;288:321-33.
8. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.[Erratum appears in Breast Cancer Res Treat. 2008 Jan;107(2):307-8]. Breast Cancer Res Treat. 2008;107:103-11.
9. Santen RJ. Risk of breast cancer with progestins: critical assessment of current data. Steroids. 2003;68:953-64.
10. Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D'Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523:313-7.
11. Hellgren M, Conard J, Norris L, Kluft C. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas. 2009;62:287-93.
12. Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One. 2014;9:e84698.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint-Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. Phys Ther. 2009;89:873-80.
14. GA Wells BS, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012.
15. Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-73.
16. Espie M, Daures J-P, Chevallier T, Mares P, Micheletti M-C, De Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol. 2007;23:391-7.
17. Cordina-Duverger E, Truong T, Anger A, Sanchez M, Arveux P, Kerbrat P, Guenel P. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013;8:e78016.
18. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception. 2007;75:S155-160.
19. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, Investigators WHI. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. Jama. 2003;289:3243-53.
20. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D, Martin L, Ockene J, Rohan T, Schenken R, Wactawski-Wende J. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13:476-86.
21. Lyytinen H, Dyba T, Ylikorkala O, Pukkala E 2009 A case-control study on hormone therapy as a risk factor for breast cancer in Finland. Maturitas Conference: 8th European Congress on Menopause, EMAS London United Kingdom. Conference Start: 20090516 Conference End: 20090520 Sponsor: PANTARHEI BIOSCIENCE, FSDeducation.eu. Conference Publication: (var.pagings). 63:S50
22. Lyytinen H, Dyba T, Pukkala E, Ylikorkala O. Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: National-wide case-control study from Finland. Int J Cancer. 2010;127(1):185-9.
23. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65-73.
24. Santen RJ. Menopausal hormone therapy and breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 2013;142:52-61.